US 11,324,698 B2Granted

Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal

AssigneeVGSK Technologies, Inc.

InventorsKameswari S. Konduri, Sandhya N. Nandedkar, Nejat Duzgunes, Pattisapu Ram Jogi Gangadharam

Life of this patent

Estimating the term…

Loading patent…

Abstract

The application disclosure provides a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and the selected drug effective for the treatment of airway hypersensitivity and inflammation such as of the lungs of a mammal as an aerosol, and a method of treatment using the composition. The composition disclosed herein provides effective treatment for the longer of a period of time at least twice as long as the selected drug alone or up to at least one week.

Claims17

Dependent claims

A method for treating lung inflammation or airway hyperreactivity, comprising:

administering to a subject in need thereof an aerosol formulation or intranasal formulation comprising a drug in an amount that is therapeutically effective for treating lung inflammation or airway hyperreactivity,
wherein the drug is encapsulated in a sterically stabilized liposome carrier comprising a phosphatidylcholine (PC), a phosphatidylglycerol (PG), and a poly (ethylene glycol) distearoylphosphatidyl ethanolamine (PEG-DSPE),
wherein the aerosol formulation has a particulate size of more than 0.2 micrometers and up to 5 micrometers, and
wherein the PC comprises synthetic palmitoyloleoyl-PG (POPC) and/or the PG comprises synthetic palmitoyloleoyl-PG (POPG), and wherein the sterically stabilized liposome carrier is free of cholesterol.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 16/856,349Filed 23 Apr 2020 · continuation
Priority: 28 Aug 2003
Published: US 2020/0352859 A112 Nov 2020
Granted: 10 May 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61K 9/1271
Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant: non-conventional liposomes,…
A61K 9/0073
Pulmonary tract; Aromatherapy: sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
A61K 9/127
Dispersions; Emulsions: synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/573
Substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone: substituted in position 21, e.g. cortisone,…

Family

Application60/498,609Us provisional application · filed 28 Aug 2003
Application60/498,546Us provisional application · filed 28 Aug 2003
Application10/769,034Parent of this continuation-in-part · filed 30 Jan 2004
Application60/632,181Us provisional application · filed 1 Dec 2004
Application11/287,703Parent of this continuation-in-part · filed 22 Nov 2005
Application12/218,777Parent of this continuation · filed 18 Jul 2008
Application12/218,777Parent of this continuation-in-part · filed 18 Jul 2008
Application14/453,125Parent of this continuation · filed 6 Aug 2014
US 8,846,079 B1Parent of this continuation · filed 30 Sep 2014
US 2020/0352859 A1Pre-grant publication · published 12 Nov 2020
US 2006/0115523 A1Published application
US 2015/0071988 A1Published application
US 11,324,698 B2This patent

From the US filing history. Foreign family members aren’t listed.